Last reviewed · How we verify
Peg-IFN + LD RBV for 24 weeks
Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress hepatitis C virus replication.
Pegylated interferon alpha combined with low-dose ribavirin stimulates the immune system to suppress hepatitis C virus replication. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | Peg-IFN + LD RBV for 24 weeks |
|---|---|
| Also known as | Pegasys plus Copegus |
| Sponsor | National Taiwan University Hospital |
| Drug class | Antiviral combination therapy |
| Target | Interferon alpha receptor; HCV RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Pegylated interferon alpha (Peg-IFN) is a long-acting form of interferon that activates innate and adaptive immune responses against HCV, while ribavirin (RBV) is a nucleoside analog that inhibits viral RNA synthesis and enhances interferon-mediated antiviral effects. The combination therapy works synergistically to reduce viral load and achieve sustained virological response in hepatitis C patients.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Anemia
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peg-IFN + LD RBV for 24 weeks CI brief — competitive landscape report
- Peg-IFN + LD RBV for 24 weeks updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI